Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

PRE-CLOSE TRADING STATEMENT

22 Jan 2015 07:00

RNS Number : 8047C
Cello Group plc
22 January 2015
 

FOR IMMEDIATE RELEASE 

22 JANUARY 2015

Cello Group plc

('Cello' or the 'Group')

PRE-CLOSE TRADING STATEMENT

Cello, the health and consumer strategic marketing group, today publishes the following trading update for the year ended 31 December 2014.

The Group has experienced strong trading for the year, with revenues and headline profits in line with consensus market expectations.

Highlights

- Cello Health maintains strong headline revenue growth and 20% operating margins

- Recent investments in iS Healthcare Dynamics and Promedica already bedding in well

- Recent investments in overseas expansion performing to plan

- Good momentum into 2015 from strong bookings in Q4 2014

Cello Health

Cello Health delivered double digit revenue growth, whilst maintaining 20% operating margins. The majority of Cello Health's revenues come from outside the UK, with the US being the primary overseas growth market. The acquisition of iS Healthcare Dynamics in May 2014 has proved a rapid success, reinforcing the global medical communications capability the Group can offer clients. The acquisition of Promedica in December 2014 has given Cello Health a presence on the West Coast of the USA enabling access to existing clients and the large biotech community there.

The integrated proposition and capabilities of Cello Health have resulted in the winning of a number of high profile contracts which the Group would not otherwise have secured. As a consequence, the last quarter of 2014 secured a strong new business pipeline for 2015, providing confidence for the new year. Of particular note is a multi capability contract secured from a major pharmaceutical client which is worth at least $7m a year.

Cello Signal

Full year revenue growth in Cello Signal was achieved across the year, against a tough comparator for the second half of 2013 which was influenced heavily by a one off project at the time.

The rapid transition to a digital product suite included continued investment in Pulsar, which generated an approximately £0.4m headline operating loss for the period on £1.2m of revenues. These revenues continue to grow. The acquisition of Line Digital in May 2014 has bedded in well and been fully integrated with Blonde, Signal's core technology business.

The overseas presence of Signal has been enhanced with new offices in New York, Singapore and Hong Kong, increasing the ability to service global contracts, although reducing operating margins in the short term.

Several large multi-year contracts were secured against global technology competitors, which have confirmed the validity of the growth strategy for Signal.

A restructuring charge of £0.5m has been incurred in the process of continuing the transition of Signal to delivering global technology solutions.

Bookings momentum towards the end of 2014 provides Signal with a solid platform for 2015.

Balance Sheet

Overall cash flow was delivered as planned, accounting for acquisition costs, increases and acceleration of dividend and the anticipated working capital outflow. Net debt at 31 December 2014 was approximately £7.0m, which remains well below 1 times EBITDA.

In 2014 the Group secured an extension of the existing facility with RBS until April 2018, at reduced cost.

VAT issue

Following discussion between HMRC, The Direct Marketing Association and The Charity Tax Group regarding the VAT status of the supply of certain goods and services to charities, one of Cello Signal's subsidiaries, in good faith, may not have been charging VAT on certain items to its charity clients appropriately. The Group intends to robustly defend its historical position on this issue which it believes has been in line with historical industry practice. Any backdated VAT assessment arising would be substantially contractually recoverable from clients should this be appropriate. The Group's current estimate of the maximum potential liability before recovery is between £1m and £2m and a non-headline exceptional charge would be made in the event of a claim. The Group will update on this matter as appropriate.

Outlook

The Group begins the new year with good bookings momentum from the last quarter of 2014 and, at this early stage of the year, the Board is confident of a strong trading year ahead.

Preliminary results

The preliminary results for year ended 31 December 2014 will be announced on 19 March 2015.

 

Enquiries:

Cello Group plc (www.cellogroup.com)

 

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

 

 

 

Cenkos Securities

 

Bobbie Hilliam

020 7484 4040

 

 

Buchanan

 

Mark Edwards, Sophie McNulty, Robbie Ceiriog-Hughes

020 7466 5000

www.buchanan.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPKDDPABKDKDB
Date   Source Headline
16th May 20114:35 pmRNSHolding in Company
16th May 20119:05 amRNSHolding in Company
11th May 20117:00 amRNSAdditional listing / TVR
28th Apr 201111:29 amRNSNotice of AGM and Annual Report and Accounts
11th Apr 20117:00 amRNSAcquisition
1st Apr 201112:47 pmRNSTotal Voting Rights
25th Mar 201112:25 pmRNSHolding(s) in Company
22nd Mar 20114:45 pmRNSHolding(s) in Company
22nd Mar 20114:20 pmRNSCompletion of Acquisition and Placing / TVR
15th Mar 20117:00 amRNSAcquisition and Placing
15th Mar 20117:00 amRNSFinal Results
24th Jan 201111:22 amRNSNotice of Results
19th Jan 20117:00 amRNSTrading update
27th Oct 20105:50 pmRNSHolding(s) in Company
14th Sep 20107:00 amRNSInterim Results
3rd Sep 20104:15 pmRNSHolding(s) in Company
1st Sep 20105:10 pmRNSHolding in Company
29th Jul 201012:24 pmRNSNotice of Results
22nd Jul 20107:00 amRNSBoard Appointment
22nd Jul 20107:00 amRNSPre-close trading update
19th Jul 201011:33 amRNSBoard Change
17th Jun 201010:00 amRNSHolding in Company
9th Jun 20107:00 amRNSDirector/PDMR Shareholding
7th Jun 201011:45 amRNSHolding(s) in Company
4th Jun 20101:10 pmRNSShare Option Grants
17th May 20101:15 pmRNSResult of AGM
17th May 20107:00 amRNSAGM Statement
30th Apr 20107:00 amRNSAdditional Listing / TVR
15th Apr 201012:44 pmRNSAnnual report & accounts & AGM notice
16th Mar 20107:00 amRNSFull Year Results
16th Feb 201011:41 amRNSNotice of Results
20th Jan 201010:30 amRNSHolding(s) in Company
19th Jan 20107:00 amRNSTrading Update
15th Sep 20097:00 amRNSInterim Results
10th Aug 200912:30 pmRNSChange in director's details
7th Aug 20099:45 amRNSChange of Adviser
5th Aug 20099:00 amRNSNotice of Results
3rd Jul 20097:00 amRNSTrading Statement
19th May 200912:46 pmRNSAGM Statement
15th May 20097:00 amRNSHolding(s) in Company
8th May 20092:55 pmRNSDigital capability widened
23rd Apr 20099:52 amRNSAnnual Report and Accounts
23rd Apr 20097:00 amRNSAdditional listing / TVR
16th Apr 20097:00 amRNSAdditional Listing/TVR
6th Apr 20097:00 amRNSDirector/PDMR Shareholding
2nd Apr 20095:28 pmRNSTransaction in Own Shares
1st Apr 20094:33 pmRNSTransaction in Own Shares
1st Apr 20094:33 pmRNSTransaction in Own Shares
27th Mar 20094:57 pmRNSTransaction in Own Shares
26th Mar 20094:18 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.